149 results
10-K
2023 FY
EX-10.7.8
ZVRA
Zevra Therapeutics Inc
Annual report
1 Apr 24
5:27pm
10-K
2023 FY
EX-10.31
ZVRA
Zevra Therapeutics Inc
Annual report
1 Apr 24
5:27pm
8-K
EX-10.1
ZVRA
Zevra Therapeutics Inc
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-10.1
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
8-K
EX-10.3
ZVRA
Zevra Therapeutics Inc
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.1
tjbb2z9
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.2
frrp30uuvav96y
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.5
5huc d7iy8nrof2vnagd
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.4
u41tw9t
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.1
c5rhz6 p4
15 May 23
Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results
4:14pm
8-K
EX-10.1
twnxrkq
8 May 23
Departure of Directors or Certain Officers
7:44am
8-K
EX-10.2
15vqt 28pjf5aggm
9 Jan 23
Departure of Directors or Certain Officers
7:27am
8-K
EX-10.3
2h7wu jfh
9 Jan 23
Departure of Directors or Certain Officers
7:27am
8-K
EX-10.1
ueg9 g3ke74wo1
9 Jan 23
Departure of Directors or Certain Officers
7:27am
8-K
EX-10.1
n7clbtckiewdylc
31 May 22
Entry into a Material Definitive Agreement
9:13pm
8-K
EX-10.1
5mo65yf3isl4
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am